New drug combo shows promise for rare NF1-Linked cancer in early trial
NCT ID NCT06693284
First seen Jan 08, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-phase trial tests a 28-day course of two oral drugs, mirdametinib and vorinostat, in 8 people aged 12+ with NF1 and a specific type of malignant peripheral nerve sheath tumor (MPNST). The goal is to check safety and see if the drugs shrink the tumor or change its markers before standard treatment like surgery or radiation. Participants receive the drugs, then undergo imaging and biopsies to measure effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.